Literature DB >> 3258770

Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin.

J L Moake1, N A Turner, N A Stathopoulos, L Nolasco, J D Hellums.   

Abstract

Fluid shear stress in arteries and arterioles partially obstructed by atherosclerosis or spasm may exceed the normal time-average level of 20 dyne/cm2. In vitro, at fluid shear stresses of 30 to 60 dyne/cm2 applied for 30 seconds, platelet aggregation occurs. At these shear stresses, either large or unusually large von Willebrand factor (vWF) multimers in the suspending fluid exogenous to the platelets mediates aggregation. Adenosine diphosphate (ADP) is also required and, in these experiments, was released from the platelets subjected to shear stress. At 120 dyne/cm2, the release of endogenous platelet vWF multimers can substitute for exogenous large or unusually large vWF forms in mediating aggregation. Endogenous released platelet vWF forms, as well as exogenous large or unusually large vWF multimers, must bind to both glycoproteins Ib and the IIb/IIIa complex to produce aggregation. Shear-induced aggregation is the result of shear stress alteration of platelet surfaces, rather than of shear effects on vWF multimers. It is mediated by either large plasma-type vWF multimers, endogenous released platelet vWF forms, or unusually large vWF multimers derived from endothelial cells, requires ADP, and is not inhibited significantly by aspirin. This type of aggregation may be important in platelet thrombus formation within narrowed arterial vessels, and may explain the limited therapeutic utility of aspirin in arterial thrombosis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3258770

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  56 in total

1.  In vitro bleeding test with PFA-100-aspects of controlling individual acetylsalicylic acid induced platelet inhibition in patients with cardiovascular disease.

Authors:  A J Peters; M Borries; F Gradaus; T W Jax; F C Schoebel; B E Strauer
Journal:  J Thromb Thrombolysis       Date:  2001-12       Impact factor: 2.300

Review 2.  Aspirin in patients with coronary artery disease: is it simply irresistible?

Authors:  G V Nair; C J Davis; M E McKenzie; D R Lowry; V L Serebruany
Journal:  J Thromb Thrombolysis       Date:  2001-04       Impact factor: 2.300

3.  Nonlinear flow affects hydrodynamic forces and neutrophil adhesion rates in cone-plate viscometers.

Authors:  H Shankaran; S Neelamegham
Journal:  Biophys J       Date:  2001-06       Impact factor: 4.033

Review 4.  Current understanding of the pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  S L Allford; S J Machin
Journal:  J Clin Pathol       Date:  2000-07       Impact factor: 3.411

5.  Three-dimensional numerical simulations of physiological flows in a stented coronary bifurcation.

Authors:  V Deplano; C Bertolotti; P Barragan
Journal:  Med Biol Eng Comput       Date:  2004-09       Impact factor: 2.602

6.  Historical perspective on ADP-induced platelet activation.

Authors:  Marian A Packham; Margaret L Rand
Journal:  Purinergic Signal       Date:  2011-04-02       Impact factor: 3.765

7.  Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions.

Authors:  S Goto; Y Ikeda; E Saldívar; Z M Ruggeri
Journal:  J Clin Invest       Date:  1998-01-15       Impact factor: 14.808

8.  Von Willebrand factor, paravalvular leak, and a new vista for TAVR.

Authors:  Neal S Kleiman; Michael J Reardon
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

Review 9.  A risk-benefit assessment of aprotinin in cardiac surgical procedures.

Authors:  W B Dobkowski; J M Murkin
Journal:  Drug Saf       Date:  1998-01       Impact factor: 5.606

10.  von Willebrand factor binding to platelet GpIb initiates signals for platelet activation.

Authors:  M H Kroll; T S Harris; J L Moake; R I Handin; A I Schafer
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.